-+ 0.00%
-+ 0.00%
-+ 0.00%

Quince Therapeutics amends 8-K to correct reverse stock split description

PUBT·06/26/2026 20:31:55
Listen to the news
Quince Therapeutics amends 8-K to correct reverse stock split description
  • Quince Therapeutics filed an amended 8-K to correct an error in its disclosure of a planned reverse stock split.
  • The amendment restated the terms as a 1-for-20 reverse split, effective 11:59 p.m. ET June 29, 2026.
  • Split-adjusted trading is set to start at the June 30, 2026 market open under ticker QNCX with new CUSIP 22053A305.
  • Shares outstanding are expected to fall to about 977,963 from 19,559,257, with fractional shares rounded up.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-285572), on June 26, 2026, and is solely responsible for the information contained therein.